Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and compelling new data demonstrating the transformative impact of its platform. Evvy now serves over 75,000 patients and partners with more than 2,000 healthcare providers through its advanced vaginal microbiome testing and precision care platform.
Vaginal discomfort is one of the most common reasons women seek medical care. Yet, the current standard of care frequently falls short, with misdiagnosis rates exceeding 60% and recurrence rates above 50%. Recent research underscores the critical role of the vaginal microbiome in regulating reproductive tract inflammation, highlighting its influence across the female lifespan, from fertility and pregnancy to long-term gynecologic health.
Evvy has developed the first and only comprehensive vaginal microbiome test coupled with a precision care platform. The platform integrates CLIA/CAP/CLEP-certified metagenomic sequencing, prescription clinical care, and personalized 1:1 health coaching, offering a holistic approach to women’s reproductive health. New data from Evvy underscores the effectiveness of this model:
- Root cause identification: Among patients experiencing previously unresolved vaginal symptoms, 90% identified a potential underlying cause through their first Evvy test.
- Fertility insights: 75% of asymptomatic patients seeking fertility support were found to have a treatable vaginal microbiome imbalance, providing a previously overlooked avenue for intervention.
- UTI-related findings: In 47% of patients reporting recent urinary tract infections (UTIs), Evvy detected UTI-associated bacteria in the vaginal microbiome, highlighting a frequently ignored contributor to recurrent infections.
- Fertility-focused support: Over 12,000 women have benefited from Evvy’s fertility-related insights, gaining clarity on how the vaginal microbiome influences reproductive health outcomes.
This growing body of evidence complements recent peer-reviewed studies validating the robustness of Evvy’s test and demonstrating significant improvements in patient outcomes.
Dr. [Evvy Spokesperson], co-founder and Chief Scientific Officer of Evvy, emphasized the platform’s potential: “What excites me most is that we’re only scratching the surface of the power of insights in the vaginal microbiome. With every test, treatment, and study, we’re building the evidence base that will redefine care for millions of women. Evvy is turning scientific insights into actionable, personalized care, improving outcomes across infections, fertility, and beyond.”
Evvy’s platform now supports the world’s largest and most comprehensive vaginal microbiome dataset, enabling groundbreaking research that could reshape the future of women’s healthcare. This dataset is informing studies in key areas such as in vitro fertilization (IVF), preterm birth prevention, UTI management, and gynecologic cancer research.
In one of its most recent initiatives, Evvy launched a fertility study exploring the previously underappreciated role of the vaginal microbiome in conception and implantation. Early results suggest that optimizing vaginal microbial balance prior to conception may significantly improve fertility success rates—a potential breakthrough poised to transform care for millions of women navigating fertility challenges.
Beyond fertility, Evvy is expanding its precision health platform to address new frontiers in women’s health. Planned studies include longitudinal monitoring of hormonal transitions such as menopause, identification of predictive biomarkers for pregnancy outcomes, and early detection of disease. By integrating its unparalleled dataset, expansive clinical network, and engaged patient community, Evvy aims to shift the paradigm in women’s healthcare, turning complex biological processes into actionable insights for personalized care.
“Evvy’s mission has always been to demystify the female body,” Dr. [Evvy Spokesperson] added. “By combining advanced metagenomic testing with personalized treatment and coaching, we’re building a future in which women receive the precise, data-driven care they deserve—care that not only addresses symptoms but improves long-term health outcomes.”
As Evvy continues to scale its platform and generate new clinical evidence, the company is positioned to lead a new era in women’s health—one in which the vaginal microbiome is recognized not just as a biological curiosity, but as a vital roadmap for improving women’s reproductive and overall health. With over 75,000 patients served, Evvy is charting a path toward a future where personalized, microbiome-driven care becomes the standard, helping millions of women worldwide achieve better health outcomes.
